Neurol. praxi. 2016;17(5):287-292 | DOI: 10.36290/neu.2016.060

Current strategy for treatment of high-grade gliomas

MUDr. Petr Pospíšil^1,2, MUDr. Tomáš Kazda^1,2, prof. MUDr. Pavel Šlampa, CSc.^1,2, doc. MUDr. Radim Jančálek, Ph.D.^3,4

¹ Klinika radiační onkologie, Masarykův onkologický ústav, Brno

² Klinika radiační onkologie, LF MU, Brno

³ Neurochirurgická klinika FN u sv. Anny v Brně

⁴ Neurochirurgická klinika FN u sv. Anny v Brně, LF MU, Brno

In recent decades, there have been significant advances in the standard therapy of high-grade gliomas. New surgical procedures were introduced; radiotherapy methods were improved. It was also found that the use of chemotherapy in specific tumor types further improves the treatment effects. Diagnostic procedures developed as well. However, treatment results are still not satisfactory. The survival of patients with glioblastoma improved only by a few months in the last several decades. The mainstay of malignant gliomas treatment is always maximal safe tumor resection as feasible without functional consequences. Additional treatment depends on histology but also prognostic and predictive factors. The main traditional prognostic factors include age, performance status and the extent of resection. Novel prognostic factors are cytogenetic and molecular biomarkers, some of which may also predict response to the treatment.

Keywords: high-grade glioma, glioblastoma, radiotherapy, chemotherapy, prognostic factors, molecular biomarkers

Published: November 7, 2016  Show citation